Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has notified stock exchanges of an upcoming board meeting scheduled for Thursday, May 14, 2026. The meeting has been convened pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Board Meeting Agenda

The board meeting will take up key financial and governance matters pertaining to the company's performance for the recently concluded fiscal year. The following items are on the agenda:

Trading Window Closure

In accordance with the company's Code of Conduct for Prevention of Insider Trading and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, Alivus Life Sciences has notified its designated persons of a trading window closure. The trading window remains closed from April 01, 2026 to May 16, 2026 (both days inclusive), covering the period of approval of audited financial results for the quarter and year ended March 31, 2026.

The intimation was signed by Rudalf Corriea, Company Secretary & Compliance Officer of Alivus Life Sciences Limited, and submitted to both BSE Ltd. and the National Stock Exchange of India Ltd. on May 07, 2026.

Corporate Details

The following table outlines the key corporate and contact details of the company:

Alivus Life Sciences Limited has informed stock exchanges about receiving a significant tax demand from the Income Tax Department. The pharmaceutical company disclosed the development under Regulation 30 of SEBI Listing Regulations on March 21, 2026.

Tax Assessment Details

The Income Tax Department's Faceless Assessment Unit issued an order dated March 20, 2026, under Section 143(1) read with Section 144B of the Income Tax Act, 1961. The assessment pertains to Assessment Year 2023-24, covering Financial Year 2022-23.

Company's Response and Impact Assessment

Alivus Life Sciences has clarified that the tax order will not materially impact its financial position or operational activities. The company emphasized that this is a regular assessment process and the order is currently appealable before the appellate authority.

The management stated it will make an assessment to exercise the right to appeal against the Income Tax Department's order. This indicates the company may challenge the disallowances that led to the tax demand.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30(2) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, read with clause 20 of Para A of Part A of Schedule III. Company Secretary and Compliance Officer Rudalf Corriea signed the regulatory filing.

The company, formerly known as Glenmark Life Sciences Limited, operates from its corporate office in Mumbai's Technopolis Knowledge Park and maintains its registered office in Solapur, Maharashtra.